On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for anemia caused by low-to-intermediate-risk myelodysplastic syndromes. Under their January 2025 global licensing deal, Keros had already received a $200 million upfront cash payment in February 2025 and remains eligible for over $1.1 billion in total milestones plus tiered royalties. Keros plans to distribute 25% of the net cash proceeds from this $20 million milestone directly to its stockholders.
Financial Comparison: Small-Cap Biotech vs. Commercial Giant
Comparing Keros Therapeutics, Inc. (NASDAQ:KROS)’ Q2 2026 results against Takeda Pharmaceutical Company Limited (NYSE:TAK)’s Q1 FY2026 performance highlights the stark difference between a clinical-stage biotech and a global pharmaceutical powerhouse.
In Q2 2026, Keros Therapeutics, Inc. reported $0 in total revenue, down from $18.2 million in Q2 2025, and a net loss of $28.7 million ($1.45 per share). However, its loss narrowed from $30.7 million a year ago as research and development expenses dropped sharply to $22.3 million from $43.5 million. This cost reduction stems from transitioning elritercept’s development expenses to Takeda and completing a 2025 corporate restructuring. Supported by $257.6 million in cash and equivalents at quarter-end, Keros boasts a clean cash runway into the first half of 2028.
Takeda Pharmaceutical Company Limited, by contrast, operates at immense commercial scale. For Q1 FY2026, Takeda reported revenue of JPY 1.22 trillion (~$7.5 billion), up 10.2% on actual exchange rates despite a 0.5% slip at constant currency due to mature product headwinds. Core EPS reached JPY 154 billion, and the company reaffirmed its full-year outlook, including expected adjusted free cash flow of JPY 650 billion to JPY 750 billion.
Financially, TAK is clearly doing better in terms of top-line revenue, commercial cash generation, and operating profit. However, KROS is executing exceptionally well for a clinical-stage firm by offsetting R&D burn through Takeda’s balance sheet, maintaining zero debt burden, and returning capital to shareholders.
Bull and Bear Cases
The bull case for Keros centers on non-dilutive capital and major pipeline upside. Successful Phase 3 trials for elritercept could unlock over $1.1 billion in future milestone payments and high-margin royalties, while its cash cushion covers operations through 2028. The bear case stems from its reliance on a single lead clinical candidate and total dependence on Takeda for commercial execution outside China.
For Takeda, the bull case rests on its steady cash flow, high-margin core portfolio (like Entyvio), and low-risk expansion via partnered late-stage assets. The bear case involves patent expirations on mature drugs and modest top-line growth at constant currency.
Hedge Fund Sentiment
Institutional positioning reflects recent sector-wide caution for both tickers. Keros Therapeutics saw hedge fund ownership dip from 27 funds in Q4 2025 to 23 funds in Q1 2026. Among holders, NVerses Capital (led by Jb Kim) held 13,124 shares valued at $140,426 (0.22% of portfolio).
Takeda similarly experienced a slight decline, with hedge fund holders dropping from 19 in Q4 2025 to 18 in Q1 2026. However, top funds increased exposure: Walleye Capital (Will England) expanded its CALL position by 764% to 38,000 shares ($609,140 value), while Pzena Investment Management (Richard S. Pzena) boosted its stake by 34% to 37,820 shares ($606,253 value).
Conclusion: What Investors Should Watch Next
Investors in Keros Therapeutics, Inc. (NASDAQ:KROS) should watch for Phase 3 ELRiSE trial enrollment progress and the timing of the 25% cash distribution from the $20 million payment. For Takeda Pharmaceutical Company Limited (NYSE:TAK), investors should track upcoming commercial product launches and constant-currency revenue recovery to offset patent cliff pressures.
While we acknowledge the risk and potential of KROS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KROS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center